Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEMAFORCRANIO: Semaglutide for hypothalamic obesity after craniopharyngioma in adolescents
2024-511114-20-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypothalamic obesity (HO) comparing Semaglutide from week 0 with Placebo then semaglutide from week 40 (2 arms). Planned start Apr 2026; status: authorised.
02
Drugs
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on 2024-511114-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511114-20-00.